An ALK2/BMP type 1 receptor kinase inhibitor has been studied in pre-clinical models for other disease processes (i.e., fibrodysplasia ossificans progressiva) associated with ACVR1 with good results. This evidence concerns the gene ACVR1 and fibrodysplasia ossificans progressiva.